| Flatirons Health & Rehab, Llc | |
| 1107 Century Dr, Louisville, Colorado 80027 | |
| (720) 507-3447 | |
| Name | Flatirons Health & Rehab, Llc |
|---|---|
| Location | 1107 Century Dr, Louisville, Colorado |
| Certified By | Medicare |
| No. of Certified Beds | 45 |
| Occupancy Rate | 82.22% |
| Medicare ID (CCN) | 065421 |
| Legal Business Name | Flatirons Health And Rehab Llc |
| Ownership Type | For Profit - Limited Liability Company |
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale.
Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Science professionals, doctoral and postdoctoral students from across the country will gather May 20 through 27 at the MDI Biological Laboratory in Bar Harbor, Maine, for an intensive one-week course in Quantitative Fluorescence Microscopy.
3M has received an "approvable" letter from the U.S. Food and Drug Administration (FDA) in response to its supplemental new drug application on Aldara (imiquimod) Cream, 5% for the treatment of superficial basal cell carcinoma (sBCC), a common form of non-melanoma skin cancer.
Bolder BioTechnology, Inc. today announced that it has been awarded a total of $1.2 million in Qualifying Therapeutic Discovery Project Grants. Grants were awarded for qualified investments under the Qualifying Therapeutic Discovery Project Tax Credit Program, which authorized up to $1 billion in tax credits or grants to biopharmaceutical companies with 250 or fewer employees.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|